IMVARIA is a health tech company pioneering AI-driven digital biomarker solutions that empower clinicians to make accurate diagnoses and prognoses at earlier stages of disease and reduce the need for invasive biopsy testing. Founded in 2019 by physician-engineers from Google and Stanford University, the company operates its AI Lab with automated, machine-learning algorithm technology to transform clinical decision-making into data science. Based in Berkeley, CA, IMVARIA is also supporting biopharmaceutical partners by optimizing pre-trial patient stratification and identifying new AI biomarker opportunities for therapeutic development.

IMVARIA specializes in AI-driven digital biomarker solutions for lung diseases, especially interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF). Their notable FDA-authorized tools include Fibresolve, an AI biomarker assisting in non-invasive diagnosis of lung fibrosis, and ScreenDx, a screening algorithm to assess interstitial lung disease. The company's AI Lab leverages advanced machine learning algorithms across diverse clinical and laboratory datasets to improve diagnostic accuracy, prognostic predictions, and clinical decision-making, aiming to reduce invasive biopsy procedures for patients. Their platform supports clinicians, health systems, and clinical trials, driving innovations in digital diagnostics and AI biomarker development.